Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Population:
Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).
Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.
These 5 cohorts will be subject to standardized clinical monitoring.
This study is proposed by the Rheumatology and Pediatrics departments of the 3 French-speaking Universities.
The first objective will be to include a progressive number of new young patients (≤ 50 years) in order to optimize and standardize care and clinical response objectives. The number of 25% of new incident cases will be sought with an increase of 20% each year during the 5 to 10 years of this project.
Population: JIA, RA/UA, SLE, dSS (American Congres of Rheumatology criteria). Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.
These 5 cohorts will be subject to standardized clinical monitoring and specific objectives that will make it possible to analyze the number of patients with a good control of the disease and/or a clinical remission, defined according to the international criteria.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| juvenile idiopathic arthritis (JIA) | aged <= 16 y.o. recent diagnosis of JIA and DMARDs treatment-naive patients; aged <18 y.o. recent diagnosis of JIA | ||
| rheumatoid arthritis (RA) | aged =>18; =< 50 y.o. recent diagnosis of RA and DMARDs treatment-naive patients | ||
| diffuse systemic sclerosis (dSS) | aged =>18; =< 50 y.o. recent diagnosis of dSS and DMARDs treatment-naive patients | ||
| seronegative arthritis (UA) | aged =>18; =< 50 y.o. recent diagnosis of UA and DMARDs treatment-naive patients | ||
| systemic lupus erythematosus (SLE) | aged =>18; =< 50 y.o. recent diagnosis of SLE and DMARDs treatment-naive patients |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Remission rate or absence of synovitis in Rheumatoid arthritis patients | Through the entire study, during approximately 15 years |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Remission rates improvement in Juvenile arthritis (JIA) patients | Through the entire study, during approximately 15 years | |
| Reduction in damage rate in Systemic Lupus Erythematosus patients | Through the entire study, during approximately 15 years |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Patrick Durez | Contact | +32 02 764 53 89 | patrick.durez@uclouvain.be |
| Name | Affiliation | Role |
|---|---|---|
| Patrick Durez, Pr | UCLouvain - IREC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCLouvain | Recruiting | Brussels | 1200 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001171 | Arthritis, Juvenile |
| D001172 | Arthritis, Rheumatoid |
| D015535 | Arthritis, Psoriatic |
| D008180 | Lupus Erythematosus, Systemic |
| D045743 | Scleroderma, Diffuse |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
residual blood and urine sampling
| Inclusion of at least 80% of the incident cases of diffuse Systemic sclerosis | Through the entire study, during approximately 15 years |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D025242 | Spondylarthropathies |
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D011565 | Psoriasis |
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D012595 | Scleroderma, Systemic |